- Remove All
- Your shopping cart is currently empty
NHI-2 is a lactate dehydrogenase A (LDHA) inhibitor with an IC50 value of 14.7 µM, demonstrating high selectivity for LDHA over LDHB, for which the IC50 is 55.8 µM. NHI-2 functions as an efficient anti-glycolytic agent, enhancing apoptosis, inducing cell cycle arrest at the S and G2 phases, and exerting broad-spectrum antiproliferative effects in cancer cells. NHI-2 additionally affects extracellular acidification rates and ATP production and has demonstrated tumor growth suppression in murine B78 melanoma models, highlighting its role in cancer metabolism research.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $40 | In Stock | |
5 mg | $94 | In Stock | |
10 mg | $147 | In Stock | |
25 mg | $293 | In Stock | |
50 mg | $439 | In Stock | |
100 mg | $635 | In Stock | |
200 mg | $893 | In Stock |
Description | NHI-2 is a lactate dehydrogenase A (LDHA) inhibitor with an IC50 value of 14.7 µM, demonstrating high selectivity for LDHA over LDHB, for which the IC50 is 55.8 µM. NHI-2 functions as an efficient anti-glycolytic agent, enhancing apoptosis, inducing cell cycle arrest at the S and G2 phases, and exerting broad-spectrum antiproliferative effects in cancer cells. NHI-2 additionally affects extracellular acidification rates and ATP production and has demonstrated tumor growth suppression in murine B78 melanoma models, highlighting its role in cancer metabolism research. |
Targets&IC50 | LDHA:14.7 µM |
In vitro | Methods: B78 cells were treated with NHI-2 (12-40 μM, 72 h), and cell proliferation was monitored in real-time using the IncuCyte™ S3 live-cell imaging system. Results: NHI-2 completely inhibited cell proliferation at 40 μM, with an EC50 value of 25 μM. [6] |
In vivo | Methods: NHI-2 (1 mg/kg, once daily for 15 consecutive days) was administered via intratumoral injection to B78 melanoma mouse models to evaluate the efficacy of lactic acid dehydrogenase inhibitors (LDHIs) in combination with immune checkpoint inhibitors (ICIs) and radiotherapy (RT). Results: The combined use of LDHIs, ICIs, and RT significantly reduced tumor volume and increased the CD8:Treg cell ratio, indicating enhanced anti-tumor immune response. [6] |
Synonyms | NHI2 |
Molecular Weight | 335.28 |
Formula | C17H12F3NO3 |
Cas No. | 1269802-97-2 |
Smiles | C(F)(F)(F)C1=C2C(N(O)C(C(OC)=O)=C2)=CC(=C1)C3=CC=CC=C3 |
Relative Density. | 1.36 g/cm3 (Predicted) |
Color | White |
Appearance | Solid |
Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
Solubility Information | DMSO: 20 mg/mL (59.65 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.